Search

Your search keyword '"Pegoretti, A."' showing total 86 results
Start Over Author "Pegoretti, A." Journal value in health
86 results on '"Pegoretti, A."'

4. PCN116 BUDGET-IMPACT ANALYSIS OF THE INTRODUCTION OF REGORAFENIB IN BRAZILIAN SUPPLEMENTARY HEALTHCARE SYSTEM AS A SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH SORAFENIB

Author

R. Palhares, B Pegoretti Rosa, Luciano Paladini, R. Saad, N. Bergamelli Ramos, E.P. Nardi, and L. Yamamoto

Subjects
Oncology, Sorafenib, medicine.medical_specialty, Second line treatment, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Budget impact, medicine.disease, chemistry.chemical_compound, chemistry, Regorafenib, Internal medicine, Hepatocellular carcinoma, medicine, Previously treated, business, Healthcare system, medicine.drug
Published
2019

12. Newest Target Therapy And Immunotherapy for the Treatment of Advanced Melanoma: Patterns of Adoption By the Private Health Care Sector in Brazil

Author

L Feijo, Z Moraes, B Pegoretti Rosa, LG Clark, and L Goes

Subjects
medicine.medical_specialty, business.industry, Health Policy, medicine.medical_treatment, Public Health, Environmental and Occupational Health, Alternative medicine, Immunotherapy, Health care, Immunology, medicine, Target therapy, Intensive care medicine, business, Advanced melanoma
Published
2017

14. Bevacizumab for Breast Cancer: Scientific Evidence Versus Real World Data (RWD) in Brazil

Author

B Pegoretti Rosa, L Feijo, L Goes, Z Moraes, and LG Clark

Subjects
Gynecology, medicine.medical_specialty, Bevacizumab, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Alternative medicine, medicine.disease, Scientific evidence, Breast cancer, medicine, Medical physics, business, Real world data, medicine.drug
Published
2017

15. Ideal Vial Size for Bortezomib: Real-World Data on Waste and Cost Reduction in Treatment of Multiple Myeloma in Brazil

Author

Fábio Santos, B Pegoretti, LG Clark, Denizar Vianna, Vanessa Teich, Fabíola Puty, Otavio Clark, T Engel, Anna Flávia Fortes, and Ana Paula Beltran Moschione Castro

Subjects
medicine.medical_specialty, Antineoplastic Agents, Medical Waste, Vial, Drug Costs, Toxicology, Cost Savings, medicine, Humans, Treatment costs, Drug Packaging, Multiple myeloma, Retrospective Studies, Body surface area, business.industry, Bortezomib, drug waste, Health Policy, bortezomib, Public Health, Environmental and Occupational Health, medicine.disease, Boronic Acids, Confidence interval, Surgery, cost-reduction, Models, Economic, Outcome and Process Assessment, Health Care, Treatment Outcome, myeloma, Pyrazines, Cost of treatment, Health Services Research, Multiple Myeloma, business, Real world data, Brazil, medicine.drug
Abstract

Objectives Single-size vials of drugs may be a source of waste and increase in treatment costs. Bortezomib, indicated for multiple myeloma (MM) treatment, is available in 3.5-mg vials, a quantity higher than the average dose commonly prescribed. This analysis aimed to demonstrate, through real-world data, which would be the optimal vial presentation for bortezomib in Brazil and quantify the reduction in medication waste related to this option. Methods From November 2007 to October 2009 all patients with MM treated with bortezomib were identified via the Evidencias database. Analysis of prescribed, dispensed, and wasted doses, their costs and projections of the ideal vial size were performed. Results Thirty-five patients (mean body surface area of 1.73 m 2 ) received 509 infusions in 131 cycles of treatment (average of 3.77 cycles per patient). The average dose prescribed was 2.1 mg per infusion (95% confidence interval [CI] 1.97–2.26) with average waste of 39.5% of the vial content (95% CI 35.35–43.76). The mean waste per patient per day was 1.38 mg (95% CI 1.24–1.52). If a 3-mg vial were available, the average drug waste per patient per day would be 0.88 mg (95% CI 0.74–1.03) or 36.2% less. With a 2.5-mg vial the waste would be 1.05 mg (95% CI 0.81–1.29) or 23.9% less. If two presentations were available (2.5 mg and 0.5 mg), the waste would be 0.52 mg (95% CI 0.4–0.63) or 62.5% less. Considering the price of the different vials to be proportional to the original 3.5-mg vial, the cost would be also reduced by the same rates described above. Conclusions A simple adjustment in vial size may reduce the waste of bortezomib by 36% to 62% and can also reduce the cost of treatment.

Published
2011
Full Text
View/download PDF

18. Patterns of Care with Biological Drugs for Ankylosing Spondylitis: Real-World Data from the Private Healthcare Market in Brazil

Author

B Pegoretti, P. Medina, A Bottoni, Z Moraes, N Rodrigues, and L Goes

Subjects
Patterns of care, Ankylosing spondylitis, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Alternative medicine, medicine.disease, Data science, Biological drugs, Medicine, Private healthcare, Medical emergency, business, Real world data
Published
2015

19. Standards Of Surgical Materials Usage In Anterior Cruciate Ligament (Acl) Surgery In Brazil Under The Perspective Of The Private Health Care System

Author

Luciano Paladini, Otavio Clark, AP Castro, AF Alves, P. Medina, and B Pegoretti

Subjects
medicine.medical_specialty, medicine.anatomical_structure, business.industry, Health Policy, Anterior cruciate ligament, Perspective (graphical), Health care, Public Health, Environmental and Occupational Health, Alternative medicine, Physical therapy, Medicine, business
Published
2015

20. PCN24 EFFICACY OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE (GEM) COMPARED TO SURGERY-ONLY IN PATIENTS WITH RESECTED PANCREATIC CANCER: SYSTEMATIC REVIEW (SR) AND METAANALYSIS (MA)

Author

B Pegoretti, E Faleiros, Luciano Paladini, Otavio Clark, Lgo Clark, and T.E.A. Botrel

Subjects
Oncology, medicine.medical_specialty, Adjuvant chemotherapy, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Gemcitabine, Surgery, Internal medicine, Pancreatic cancer, medicine, In patient, business, medicine.drug
Published
2010
Full Text
View/download PDF

21. PCN124 IDEAL VIAL SIZE FOR BORTEZOMIB: REAL WORLD DATA ON WASTE AND COST REDUCTION IN MULTIPLE MYELOMA (MM)

Author

T Engel, AP Castro, AF Alves, F.P.S. Santos, B Pegoretti, Otavio Clark, and Lgo Clark

Subjects
Ideal (set theory), Bortezomib, Computer science, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Vial, Cost reduction, medicine, Operations management, Real world data, health care economics and organizations, Multiple myeloma, medicine.drug
Published
2010
Full Text
View/download PDF

23. PCN166 TRAZTUZUMAB ON ADJUVANT BREAST CANCER TREATMENT: EVIDENCE SYNTHESIS AND A HEALTH TECHNOLOGY EVALUATION

Author

E Faleiros, LG Clark, B Pegoretti, T Engel, Otavio Clark, and Luciano Paladini

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Health Policy, Public Health, Environmental and Occupational Health, Health technology, medicine.disease, Breast cancer, Internal medicine, Medicine, business, Adjuvant, Evidence synthesis
Published
2009
Full Text
View/download PDF

24. PCN164 TWO DIFFERENT DOSES OF PALONOSETRON (PAL) FOR PREVENTION OF CHEMOTHERAPY-INDUCED VOMITING (CIV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)

Author

T Engel, E Faleiros, LG Clark, B Pegoretti, Luciano Paladini, and Otavio Clark

Subjects
Chemotherapy induced, business.industry, Meta-analysis, Anesthesia, Health Policy, Palonosetron, medicine, Vomiting, Public Health, Environmental and Occupational Health, In patient, medicine.symptom, business, medicine.drug
Published
2009
Full Text
View/download PDF

27. PCN35 BUDGETARY IMPACT OF ORAL CHEMOTHERAPY: REAL-WORLD DATA ANALYSIS FROM PAYERS' PERSPECTIVES IN BRAZIL

Author

AP Castro, FS Santos, Luciano Paladini, E Faleiros, T Engel, B Pegoretti, Otavio Clark, LG Clark, and AF Alves

Subjects
medicine.medical_specialty, Oral chemotherapy, business.industry, Health Policy, Alternative medicine, medicine, Public Health, Environmental and Occupational Health, Budgetary impact, Public administration, business, Real world data
Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results